PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

Download PDF Copy

Jun 9 2010

NewsGuard 100/100 Score

PharmaMar SA (Grupo Zeltia, ZEL.MC) today announced that a registration trial in relapsed/refractory multiple myeloma patients has been initiated with Aplidin(R) (plitidepsin) in combination with dexamethasone versus dexamethasone alone.

This pivotal, international, multicenter Phase III clinical trial, called ADMYRE, will enroll 300 patients in 60 medical centers across 20 countries (including the U.S., Europe, Asia and South America), with an estimated recruitment period of 24 months. The primary objective of ADMYRE is Progression Free Survival (PFS).

Aplidin(R) is an anti-tumor agent originally isolated from the Mediterranean tunicate Aplidium albicans and currently obtained by chemical synthesis. Aplidin(R) is the second most advanced compound in clinical development at PharmaMar.

SOURCE PharmaMar

Posted in: Drug Trial News | Medical Condition News

Tags: Alzheimer's Disease, Biotechnology, Cancer, Clinical Trial, Compound, Dexamethasone, Multiple Myeloma, Myeloma, Nervous System, Oncology, Ovarian Cancer, Soft Tissue Sarcoma, Tumor

Comments (0)

Download PDF Copy

Suggested Reading

Clomiphene and dexamethasone boost fertility in PCOS patients

Clomiphene and dexamethasone boost fertility in PCOS patients

Proteins in the blood could warn people of cancer more than seven years before it is diagnosed

Proteins in the blood could warn people of cancer more than seven years before it is diagnosed

GLP-1 drugs found to lower cancer risk in diabetes patients

GLP-1 drugs found to lower cancer risk in diabetes patients

Researchers find the effect of pesticides on increased cancer risk is comparable to smoking for some cancers

Researchers find the effect of pesticides on increased cancer risk is comparable to smoking for some cancers

New analysis sheds light on cancer incidence and mortality trends in the UK

New analysis sheds light on cancer incidence and mortality trends in the UK

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Study addresses knowledge gap of clinical features and outcomes of Black patients with melanoma